Navigation Links
Complications Found in Proposed Prostate Cancer Treatment
Date:5/1/2008

Efforts to hinder a protein called IGF-1 not entirely successful, studies find

THURSDAY, May 1 (HealthDay News) -- The idea that prostate cancer can be treated successfully just by blocking the activity of a protein called insulin-like growth factor (IGF-1) has been undermined by two new studies.

IGF-1 blockage is a goal being pursed by a number of drug companies and academic researchers, stimulated by studies showing an association between high levels of the protein and prostate cancer risk. Many efforts are aimed at blocking the receptors for IGF-1 in prostate cancer cells.

The new studies showing that blocking IGF-1 receptors isn't as simple a matter as might be wished are published back to back in the May 1 issue of Cancer Research.

One of the studies, by a group led by Norman Greenberg, a member of the clinical research division at the Fred Hutchinson Cancer Research Center in Seattle, found an unexpected interaction with a tumor suppressor gene, p53. The researchers created mice whose prostate cells lacked receptors for IGF-1 and crossed them with mice whose P53 gene function was crippled.

"When the function of p53 is abrogated, the cancers seem to accelerate," Greenberg said. "So when you interfere with the IGF-1 receptor, you might be taking the foot off the brake."

That wouldn't matter in human males whose p53 genes were working properly, Greenberg said. "What we are suggesting is that when p53 is compromised, patients might not respond as indicated," he said.

This might mean that a check of p53 function in someone with prostate cancer might be needed before IGF-1 blockage therapy is started, Greenberg said. That idea has to be checked out, he said.

"So we would get data on a patient's tumor before treatment and after treatment, and see if the status of p53 shows whether it would respond more or less to IGF-1 treatment," Greenberg said.

The other study, this one led by Dr. Pinchas Cohen, chief of pediatric endocrinology at the University of California, Los Angeles, also used mice bred to develop prostate cancer, with some also bred to lack IGF-1 receptors.

"The conventional wisdom was that without the IGF receptors, the tumors would fail to develop or be much smaller," Cohen said. "What happened was that they were not reduced in size. In fact, they were exactly the same size."

Low IGF-1 levels in the mice were accompanied by higher levels of growth hormone and insulin, which stimulated growth of the cancer cells, Cohen said.

"This doesn't argue against IGF-1 blockage as a treatment," he said. "But it shows the need for targeting multiple pathways. As the cancers find ways to overcome IGF-1 blockage, it should be used in conjunction with other therapies."

More information

Learn more about prostate cancer from the U.S. National Cancer Institute.



SOURCES: Norman Greenberg, Ph.D., Fred Hutchinson Cancer Research Center, Seattle; Pinchas Cohen, M.D., professor and chief, pediatric endocrinology, University of California, Los Angeles; May 1, 2008, Cancer Research


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Viscosity Enhancers Curb Bleeding Complications
2. FDA Examines LASIK Surgery Complications
3. Minimally invasive pancreas surgery leads to fewer complications, study finds
4. Laparoscopic Surgery on Pancreas Has Fewer Complications
5. Sleep Apnea Screening Cuts Surgical Complications
6. Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves
7. Psoriasis Poses Danger for More Serious Complications
8. New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants
9. How to effectively avoid many common complications and liver damage in bile duct exploration?
10. Obese Children Face More Complications During Surgery
11. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... ... its pervasiveness, many physicians are unfamiliar with how best to treat of NeuP, partly ... a timely review has been published in the Journal of Pain Research ... preclinical scientists on its diagnosis and choice of treatment. , The review, titled “ ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... announced today that Claritas Capital, a Nashville-based private equity firm, has invested $3.35 ... expansion plans for some time, and Claritas Capital offers the smart money, speed ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... has published a new eBook titled “ 5 Questions to Ask Before Entering ... Analyst on the Genetic Test Evaluation (GTE) team, the book explores the various ...
(Date:6/20/2017)... ... , ... AMC Health , the leading provider of proven real-time virtual ... Similar to its approach in demonstrating positive outcomes in the healthcare market, AMC Health ... value of eVisits to support virtual studies. , In a study concluded ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)... Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), a ... of stem cells, today provided a corporate update and ... 31 st , 2017. "We are ... of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. ... the first blood cancer patient in the recently initiated ...
Breaking Medicine Technology: